Stocksigma LogoStocksigma Logo

Concord Biotech Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh)

■ Revenue: 30,907 (+25.1% YoY | +20.0% QoQ) ■ EBITDA: 10,438 (+18.0% YoY | +26.7% QoQ) ■ EBITDA Margin (%): 33.8 (-205 bps YoY | +178 bps QoQ) ■ PAT: 7,065

Concord Biotech Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh)

Concord Biotech Ltd · Outcome · 28 Oct 2026, 12:33 am

Concord Biotech Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh) ■ Revenue: 30,907 (+25.1% YoY | +20.0% QoQ) ■ EBITDA: 10,438 (+18.0% YoY | +26.7% QoQ) ■ EBITDA Margin (%): 33.8 (-205 bps YoY | +178 bps QoQ) ■ PAT: 7,065 (+11.1% YoY | +20.7% QoQ) ■ EPS (INR): 6.65 (+10.3% YoY | +20.5% QoQ)

Original exchange filing (PDF)

More announcements from Concord Biotech Ltd

All Concord Biotech Ltd announcements